Gene therapy injection for advanced head and neck cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Diagnosed with recurrent or metastatic head and neck cancer (confirmed by biopsy or cell sample)
- Previously received at least one round of platinum-based chemotherapy for advanced disease, or your cancer didn't respond to or tolerate platinum drugs
- Not a candidate for surgery or radiation therapy; have at least one tumor lesion at least 2 cm that can be injected
- No recent chemotherapy, radiation, immunotherapy, or antiviral drugs (within 4 weeks)
- Life expectancy of at least 3 months; overall health status allows light activity; normal or near-normal blood counts and liver/kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new treatment plan for nasopharyngeal cancer that avoids platinum-based chemotherapy, which can have harsh side effects. It may help patients with stage II or III disease by using other drugs to control the cancer.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether giving an immunotherapy drug called adebrelimab, based on levels of EBV DNA in the blood, can help people with advanced nasopharyngeal cancer. It is for those who have finished initial chemotherapy and still have signs of the virus or stable disease.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.